Psoriatic arthritis: Epidemiology, diagnosis, and treatment

Jung-Tai Liu, Horng-Ming Yeh, Shyun-Yeu Liu, Kow-Tong Chen

Psoriatic arthritis (PsA) is a chronic disease which involves the inflammation of synovial tissue, entheses, skin and usually seronegative for rheumatoid factor[1]. Spondyloarthritis complex includes ankylosing spondylitis, reactive arthritis, arthritis associated with inflammatory bowel disease, undifferentiated spondyloarthritis, and PsA[2,3]. PsA is belonged as one part of the spondyloarthritis complex. PsA patients have heterogeneous clinical presentations, with diverse articular and dermatological features and varied disease courses and outcomes. PsA was initially considered to be a mild disease, but in the past decade, 40%-60% of patients have developed erosive and deforming joint complications[4]. PsA-induced joint damaging complications not only lead to lower articular function and higher mortality but also affect patients’ ability to work and affect their social relationships[4]. The remission of PsA symptoms has been attributed to early diagnosis and treatment in recent studies[5,6]. However, PsA is underdiagnosed in psoriasis patients, which may be due to under-recognition of PsA symptoms and a lack of effective screening tools. The aims of this article were

**Key words:** Arthritis; Psoriasis; Psoriatic arthritis; Spondyloarthritis

**Core tip:** Psoriatic arthritis, usually seronegative for rheumatoid factor, involves the inflammation of synovial tissue, entheses, skin. Clinical manifestation of psoriatic arthritis varies and is under-diagnosed in psoriasis patients. This article presented the epidemiology, diagnosis, and treatment of psoriatic arthritis and to suggest a paradigm for use in standard clinical practice.

Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop 2014; 5(4): 537-543 Available from: URL: http://www.wjgnet.com/2218-5836/full/v5/i4/537.htm DOI: http://dx.doi.org/10.5312/wjo.v5.i4.537

**INTRODUCTION**

Psoriatic arthritis (PsA) is a chronic disease which involves the inflammation of synovial tissue, entheses, skin and usually seronegative for rheumatoid factor[1]. Spondyloarthritis complex includes ankylosing spondylitis, reactive arthritis, arthritis associated with inflammatory bowel disease, undifferentiated spondyloarthritis, and PsA[2,3]. PsA is belonged as one part of the spondyloarthritis complex. PsA patients have heterogeneous clinical presentations, with diverse articular and dermatological features and varied disease courses and outcomes. PsA was initially considered to be a mild disease, but in the past decade, 40%-60% of patients have developed erosive and deforming joint complications[4]. PsA-induced joint damaging complications not only lead to lower articular function and higher mortality but also affect patients’ ability to work and affect their social relationships[4]. The remission of PsA symptoms has been attributed to early diagnosis and treatment in recent studies[5,6]. However, PsA is underdiagnosed in psoriasis patients, which may be due to under-recognition of PsA symptoms and a lack of effective screening tools. The aims of this article were
to present the epidemiology, diagnosis, and treatment of PsA and to suggest a paradigm for use in standard clinical practice.

**DATA COLLECTION**

We collected all of the articles published from January 2005 through October 2013 that described patients who were affected by PsA. By searching MEDLINE (National Library of Medicine, Bethesda, Maryland, United States), we used the key words “psoriatic arthritis” and “epidemiology of psoriatic arthritis” or “diagnosis of psoriatic arthritis” or “management of psoriatic arthritis” to obtain these articles. Articles that were not published in English, manuscripts without an abstract (which were assumed to not be original), and opinion articles were excluded from the review. The relevant information was extracted from the selecting articles and classified based on the following: PsA epidemiology, PsA diagnosis, PsA management, the setting of study, and the methodology of study.

The article searches were conducted from August 2013 to September 2013. Using the search terms previously described, a total of 853 papers were collected. All selected articles were reviewed by the authors and 109 articles were considered to be relevant. The study settings mostly located in European countries, the United States, Australia and Japan. The region that produced the most original information was Europe, which accounted for 35% of the articles. After analyzing the abstracts, we found that 85% of the studies were case reports, and 10% were retrospective. Additionally, 5% referenced other designs.

**EPIDEMIOLOGY**

It is difficult to determine the epidemiology of PsA due to the absence of universally accepted criteria for its diagnosis. The first classification criteria for PsA were proposed by Moll et al.

### Table 1 The classification for psoriatic arthritis criteria for diagnosing psoriatic arthritis-related inflammatory musculoskeletal disease (joint, spine or enthesal)

| Evidence of psoriasis (any of three) | Incidence (1/100000) | Ref. | Prevalence (1/100000) | Ref. |
|-------------------------------------|----------------------|------|-----------------------|------|
| Current: Psoriatic skin or scalp disease present, as judged by a dermatologist or rheumatologist (score of 2) | China NA | [32] | 0.001% | [33] |
| Personal history: May be obtained from the patient, family doctor, dermatologist, or rheumatologist (score of 1) | Japan 0.1 | [17] | 0.02% | [32] |
| Family history: In a first- or second-degree relative, according to patient report (score of 1) | Greece 3 | [20] | 0.17% | [29] |
| Psoriatic nail dystrophy | France NA | | 0.19% | [23] |
| Typical psoriatic Nail dystrophy, including onycholysis, pitting, and hyperkeratosis, observed on current physical examination (score of 1) | Italy NA | | 0.42% | [25] |
| Negative rheumatoid factor | Germany NA | | 0.29% | [24] |
| By any method except latex, but preferably by enzyme-linked immunosorbent assay or nephelometry, according to the local laboratory reference range (score of 1) | Finland 23.1 | [18] | NA | |
| Dactylitis | Sweden 8 | [19] | 0.02%-0.25% | [30] |
| Personal history: recorded by a rheumatologist (score of 1) | Iceland NA | | 0.14% | [28] |
| Radiological evidence of juxta-articular new bone formation | Norway NA | | 0.2% | [27] |
| Ill-defined ossification near the joint margins (but excluding osteophyte formation) on plain X-rays of the hand or foot (score of 1) | Russia NA | | 0.3% | [31] |
| Male-to-female ratio is from 0.7:1 to 2.1:1 | Americas United States 7.2 | [22] | 0.16% | [22] |
| | Argentina 6.3 | [92] | 0.07% | [21] |
| | Mexico NA | | 0.02% | [26] |

NA: Not available.

### Table 2 Comparison of the incidence and prevalence of psoriatic arthritis among several countries

| Country | Incidence (1/100000) | Ref. | Prevalence (1/100000) | Ref. |
|---------|----------------------|------|-----------------------|------|
| Asia    | China NA | [32] | 0.001% | [33] |
| Japan   | 0.1 | [17] | 0.02% | [32] |
| Europe  | NA | | NA | |
| Greece  | 3 | [20] | 0.17% | [29] |
| France  | NA | | 0.19% | [23] |
| Italy   | NA | | 0.42% | [25] |
| Germany | NA | | 0.29% | [24] |
| Finland | 23.1 | [18] | NA | |
| Sweden  | 8 | [19] | 0.02%-0.25% | [30] |
| Iceland | NA | | 0.14% | [28] |
| Norway  | NA | | 0.2% | [27] |
| Russia  | NA | | 0.3% | [31] |
| Americas United States | 7.2 | [22] | 0.16% | [22] |
| Argentina | 6.3 | [92] | 0.07% | [21] |
| Mexico | NA | | 0.02% | [26] |

PsA usually occurs in the age of 40 to 50 years old, and the disease may occur in young children and elderly patients as well. Psoriasis vulgaris is the most common type of psoriasis with PsA.

PsA usually occurs in the age of 40 to 50 years old, and the disease may occur in young children and elderly patients as well. Psoriasis vulgaris is the most common type of psoriasis with PsA. A few proportion (4%-5%) of PsA cases are related to guttate and pustular psoriasis. One to two percent of cases involve single nail without skin involvement. Male-to-female ratio is from 0.7:1 to 2.1:1. Approximately 10%-37% of patients have skin and joint disease simultaneously, and 6%-18% of patients have arthritis preceding psoriasis. Environmental factors, including infection (such as streptococcus, human immunodeficiency virus), drug use, and joint trauma (mainly in children), are known to contribute to PsA. Emotional stress plays an important role as a trigger for both skin and joint psoriasis. However, the neuroimmunoendocrine mechanisms involved in this phenomenon have not been elucidated. One population-based study suggested that pregnancy and steroid use might trigger PsA in patients with psoriasis.

Table 2 shows the incidence and prevalence of PsA worldwide. There is substantial variability in the incidence and prevalence of PsA by country. The incidence of PsA varies from 0.1/100000 in Japan to 23.1/100000 in Finland. The prevalence of PsA in Europe and America varies from 0.02%-0.42% to 2.1%.

In China, the disease prevalence is 0.02%.[21] Indians were found to have the highest prevalence of PsA among the multiethnic population in...
Patients with PsA are found to have atlantoaxial fusion or dactylitis and 50% of patients have dactylitis and enthesitis, which may be present in solo or in combination with others. The major clinical features of the disease are spondylitis (18%-46%), inflammatory neck pain (23%-39%), thoracic inflammatory pain (13%-21%), and axial symptoms (25%-50%).

Most of patients with axial involvement can be no clinical symptoms and maintain their spinal mobility with no reduction in spinal flexion or chest expansion for more than 10 years. Sacroiliitis is a common symptom among PsA patients. Usually, it occur unilaterally and then become bilaterally in the following years. A study conducted in an Italian patient population using bone scans to detect active sacroiliitis found that the prevalence of sacroiliitis was 32%/35%. A multicenter study from the United States found that the prevalence of sacroiliitis was 78%/36%. It was found that one-third of PsA patients developed sacroiliitis after 5 years of illness and that half of patients developed sacroiliitis by 10 years. Longer period of disease may be the cause of higher prevalence of sacroiliitis. Males have a three-fold greater risk of developing sacroiliitis than females have. The onset time of PsA at younger age has higher risk to hip joint disease, however, there is no significant association between occurrence of enthesitis, dactylitis, and peripheral arthritis with the occurrence of hip joint disease.

PsA can simulate rheumatoid arthritis to involve the knee or a large joint with some small joints in fingers or toes (Figure 1). Polyarthritis is generally symmetrical and has dactylitis and enthesitis. Oligoarthritis can be associated with dactylitis. It is also found a shortening of the fingers with pencil-in-cup deformity. Dactylitis was present in 32%-48% of patients with PsA in various studies. Seventy-five percent of patients have toes with dactylitis and 50% of patients have multiple digits involved simultaneously. The morbidty of dactylitis increases as the duration of disease prolongs.

Twenty-five to fifty three percent of PsA patients present enthesitis. One study in Canada demonstrated that only 15% of patients had enthesitis at the beginning of treatment, but the incidence increased to 36% as the disease progressed. The Achilles tendon, plantar fascia, and greater trochanter are the most common sites affected.

From 4% to 18% of patients with PsA are found to have acute anterior uveitis. Uveitis is more common in PsA patients with the spondylitis, with or without peripheral joint involvement. However, uveitis is uncommonly clinical presentation in Spain and Israel. The prevalence of uveitis among PsA patients in these areas is only 1%-3%.

Imaging findings

Radiography, ultrasonography, magnetic resonance imaging (MRI), computed tomography (CT), and bone scintigraphy are imaging techniques for diagnosis of PsA. In recent years, MRI and ultrasonography are increasingly used for assessment of PsA, providing additional information of the pathogenesis of the disease.

The most characteristic radiological finding indicative of PsA is bone destruction and proliferation. Figure 2 shows the characteristics of radiological findings of peripheral PsA: an asymmetrical distribution, distal interphalangeal joints involvement, periostitis, bone density preservation, bone ankylosis, and pencil-in-cup deformity. Axial involvement includes paravertebral ossification, syndesmophytes, interspinous or anterior ligament calcification, apophysis, sclerosis, and asymmetrical sacroiliitis. Cervical intervertebral discs may be narrowed, and ankylosis may be present with atlantoaxial fusion or subluxation. Bone erosion and condyle osteolysis.
The basic goals of PsA treatment are helping patient to alleviate from the suffering of the disease, to preserve the joint structure, to improve patients’ physical activities, and to reduce the risk of mortality. As a rule, all PsA patients must be informed of the characteristics of the disease and given psychological counseling and physiotherapy.

**Corticosteroids**

Mild forms of the disease may respond to nonsteroidal inflammatory agents, which are occasionally given in combination with intra-articular glucocorticoid injections. Intra-articular corticosteroids may represent a therapeutic option in cases of mono- or oligoarticular joint involvement in PsA. The systemic use of corticosteroids is not recommended due to a lack of evidence regarding its efficacy and due to the risk of severe adverse events and relapse of skin psoriasis upon discontinuation.

**Nonsteroidal anti-inflammatory drugs**

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as an initial therapy for both peripheral and axial disease. For example, according to the measurement by the American College of Rheumatology Responders Index 20 (ACR20), the treatment of PsA patients with celecoxib at a dose of 200 or 400 mg over two weeks increased their rates of clinical response by 21% and 11%, respectively. However, there was no difference in response between patients treated with celecoxib and untreated patients after 12 wk. Treatment with NSAIDs represents an option for the short-term symptomatic treatment of PsA.

**Conventional disease-modifying antirheumatic drugs**

Disease-modifying antirheumatic drugs (DMARDs) include methotrexate, oral and parenteral gold, cyclosporine, leflunomide, azathioprine and 6-mercaptopurine, antimarial agents, D-penicillamine, colchicines, retinoids, photochemotherapy, somatostatin, and sulfasalazine. Moderate to severe forms of the disease are initially treated with the same therapy as in the mild form of the disease, but with the addition of DMARDs. The efficacy of methotrexate in the treatment of PsA is controversial; although this drug is occasionally used in combination with NSAIDs, its use should be carefully monitored due to the possibility of hepatotoxicity.

Cyclosporine is an efficacious option for the treatment of PsA, and its results may be potentiated by combination with adalimumab. Leflunomide may be used in the treatment of PsA but should be carefully monitored due to its hepatotoxicity. Sulfasalazine can be used in PsA to afford pain relief.

**Anti-tumor necrosis factor agents**

Table 3 summarizes the current biological therapies for the treatment of moderate to severe psoriasis and PsA. Adult patients who have had moderate to severe active PsA (at least three swollen and painful joints) for more than six months and those with psoriatic skin lesions or a history of psoriasis and an intolerance to NSAIDs or DMARDs over three months, whether combined or not combined with methotrexate, are the indi-
The incidence and prevalence of PsA vary worldwide. The incidence and prevalence of PsA in Asia are lower than in North American and European countries. Early diagnosis and treatment for PsA improve patient’s outcomes. PsA is underdiagnosed among psoriasis patients. Physicians should be alert the possibility of PsA when a patient presents with preexisting psoriasis has arthritis. If needed, counsel a rheumatologist for help. The treatment of PsA should be considered all aspects of the disease, including clinical manifestations, mental problems, and maintenance of articular function.

REFERENCES

1  Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78 [PMID: 4581554 DOI: 10.1016/0039-0172(73)90035-8]
2  Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii4-ii17 [PMID: 15708927]
3  O’Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. *Ballieres Clin Rheumatol* 1994; 8: 245-261 [PMID: 8076386 DOI: 10.1016/0959-159X(94)80017-0]
4  Slobodin G, Rosler I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? *Isr Med Assoc J* 2009; 11: 430-434 [PMID: 19911496]
5  Helhiwell PS, Mease PJ, FitzGerald O, Taylor WJ, van der Heijde D. Peripheral spondyloarthropathy and psoriatic arthritis: overlaps and distinctions: a report from the GRAPPA 2012 annual meeting. *J Rheumatol* 2013; 40: 1446-1449 [PMID: 23906543 DOI: 10.3999/jrheum.130460]
6  Palmer D, El Miedany Y. Early psoriatic arthritis: facing the challenge. *Br J Nurs* 2013; 22: 1014-1020 [PMID: 24067311]
7  Taylor W, Gladman D, Hellwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* 2006; 54: 2665-2673 [PMID: 16871531 DOI: 10.1002/art.21972]
8  Gladman DD, Shuckett R, Russell ML, Thorne JG, Schachter RK. Psoriatic arthritis (PsA)—an analysis of 220 patients. *Q J Med* 1987; 62: 127-141 [PMID: 3659255]
9  Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subtypes and relationship of joint disease to nail and skin disease. *Br J Rheumatol* 1994; 33: 834-839 [PMID: 8081668 DOI: 10.1093/rheumatology/33.9.834]
10  Rajendran CP, LEDGE SG, RANI KP, Madhavan R. Psoriatic arthritis. *J Assoc Physicians India* 2003; 51: 1065-1068 [PMID: 1526390]
11  Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. *Br J Rheumatol* 1991; 30: 245-250 [PMID: 1863819 DOI: 10.1093/rheumatology/30.4.245]
12  Madland TM, Apalset EM, Johannessen AE, Rossebø B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. *J Rheumatol* 2005; 32: 1918-1922 [PMID: 1620347]
13  Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. *Scand J Rheumatol* 2009; 38: 251-255 [PMID: 19247847 DOI: 10.1007/s10067-009-0256-z]
14  Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. *J Rheumatol* 1998; 25: 730-733 [PMID: 9581877]
15  Mease P, Coffie BS. Diagnosis and treatment of psoriatic arthritis. *J Am Acad Dermatol* 2005; 52: 1-19 [PMID: 15627075 DOI: 10.1016/j.jaad.2004.06.013]
16  Thumboo J, Uramoto K, Shibeel MI, O’Fallon WM, Crowson CS, Gibson LE, Michet CJ, Gabriel SE. Risk factors for the development of psoriatic arthritis: a population based nested case control study. *J Rheumatol* 2002; 29: 757-762 [PMID: 11950018]
17  Uppal SS, Abraham M, Chowdhury RI, Kumari R, Pathan EM, Al Rashed A. Analysis of spondyloarthropathy and undifferentiated spondyloarthritis in Kuwait: a comparison between Arabs and South Asians. *Clin Rheumatol* 2006; 25: 219-224 [PMID: 16240074 DOI: 10.1007/s10067-005-1162-1]
18  Savolaainen E, Kaipainen-Septinen O, Kröger L, Luosujärvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio arthritis/33.9.834
19  Söderlin MK, Börjesson O, Kautiainen H, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. *Ann Rheum Dis* 2002; 61: 911-915 [DOI: 10.1136/ard.61.9.911]
20  Alamanos Y, Papadopoulos NG, Vougiouklis PV, Siosoz CS, Psychos DN, Tympounidou M, Drosos AA. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001. *J Rheumatol* 2003; 30: 2641-2644 [PMID: 1479208]
21  Soriano ER, Rosa J, Velezo E, Schipplberg M, Inamuruma PM, Diaz J, Catoggio LJ. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. *Rheumatology (Oxford)* 2011; 50: 729-734 [PMID: 21134962 DOI: 10.1093/rheumatology/keq369]
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009; 36: 361-367 [PMID: 19208565 DOI: 10.3899/jrheum.080691]

Saraux A, Guillen F, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, Cantagrel A, Charay-Valckenære I, Fillier-Ziegler L, Filippo RM, Juvin R, Behier JM, Fautrel B, Masson C, Coste J. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005; 64: 1431-1435 [PMID: 15817661 DOI: 10.1136/ard.2004.029207]

Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondyloarthropathies in HLAB27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67

De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 2007; 36: 14-21 [PMID: 17454930 DOI: 10.1080/03009740700904243]

Alvarez-Nemeyegi J, Pelaez-Ballestas I, Sanin LH, Cardiel MH, Ramirez-Angulo A, Goyoache-Robles MV. Prevalence of musculoskeletal pain and rheumatic diseases in the southeast of Spain. A COPSORD-based community survey. J Rheumatol Suppl 2011; 81: 21-25 [PMID: 21916595]

Love TJ, Gudjonssohn B, Gudjonsson JE, Valdimarsson H. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol 2007; 34: 2082-2088 [PMID: 17696270]

Trontzas P, Andrianakos A, Miyakis S, Pantelidou K, Vafiadou L, Dockerty JL, Cee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 790-794 [PMID: 15113998 DOI: 10.1093/rheumatology/keh198]

Liu JT, Gudjonssohn B, Gudjonsson JE, Valdimarsson H. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol 2007; 34: 2082-2088 [PMID: 17696270]

Trontzas P, Andrianakos A, Miyakis S, Pantelidou K, Vafiadou L, Karatzioiti V, Voudouris C. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESOR DIG study. Clin Rheumatol 2005; 24: 583-589 [PMID: 15864686 DOI: 10.1007/s10067-005-1106-9]

Haglund E, Bremander AB, Petersson IF, Strömbeck B, Bergman S, Jacobsson LT, Turkiewicz A, Geborek P, Englund M. Prevalence of spondyloarthropathies and its subtypes in southern Sweden. Ann Rheum Dis 2011; 70: 943-948 [PMID: 21289961 DOI: 10.1136/ard.2010.141598]

Alexeiea L, Krylov M, Vturin M, Verdon N, Erdesz S, Benvolenksaya L. Prevalence of spondyloarthropathies and HLA-B27 in the native population of Chuokta, Russia. J Rheumatol 1994; 21: 2298-2300 [PMID: 7699632]

Hukuda S, Minami M, Saito T, Mitsui H, Komatsubara Y, Makino H, Shibata T, Shingu M, Takasu T, Shichikawa K. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28: 554-559 [PMID: 11286958]

Liao ZT, Pan YF, Huang JL, Huang F, Chi WJ, Zhang KX, Lin ZM, Wu YQ, He WZ, Wu J, Xie XJ, Huang JX, Wei QJ, Li TW, Wu Z, Yu BY, Gu JR. An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population. Sand J Rheumatol 2009; 38: 455-459 [PMID: 19922021 DOI: 10.3199/030097490978085]

Thumboo J, Tham SN, Tay YK, Chee T, Mow B, Chia HP, Boey ML. Patterns of psoriatic arthritis in Orientals. J Rheumatol 1997; 24: 1949-1953 [PMID: 9330937]

Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994; 33: 133-138 [PMID: 8162477 DOI: 10.1093/rheumatology/33.2.133]

Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol 2009; 36: 2744-2750 [PMID: 19884276 DOI: 10.3899/jrheum.090412]

Michet CJ, Mason TG, Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis 2005; 64: 1068-1070 [PMID: 15958761 DOI: 10.1136/ard.2004.022228]

Punzi L, Planon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58: 226-229 [PMID: 10364901 DOI: 10.1136/ard.58.4.226]
De Simone C, Guerriero C, Giampetruzzi AR, Costantini M, Di Gregorio F, Amerio P. Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol 2003; 49: 217-222 [PMID: 12894068 DOI: 10.1067/s0190-9622(03)00934-6]

Spannow AH, Pfeiffer-Jensen M, Andersen NT, Herlin T, Stenbøg E. Ultrasonographic measurements of joint cartilage thickness in healthy children: age- and sex-related standard reference values. J Rheumatol 2010; 37: 2595-2601 [PMID: 20810511 DOI: 10.3899/jrheum.100101]

Schwenzer NF, Kötter I, Henes JC, Schraml C, Fritz J, Claussen CD, Horger M. The role of dynamic contrast-enhanced MRI in the differential diagnosis of psoriatic and rheumatoid arthritis. AJR Am J Roentgenol 2010; 194: 715-720 [PMID: 20173150 DOI: 10.2214/AJR.09.2671]

Schoellnast H, Deutschmann HA, Hermann J, Schaffler GJ, Reittner P, Kammerhuber F, Szolar DH, Preidler KW. Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol 2012; 26: 805-822 [PMID: 23273793 DOI: 10.1016/j.berh.2012.09.004]

Gutierrez M, Filippucci E, De Angelis R, Filosa G, Kane D, Grassi W. A sonographic spectrum of psoriatic arthritis: "the five targets". Clin Rheumatol 2010; 29: 133-142 [PMID: 19851707 DOI: 10.1007/s10067-009-1292-y]

Naredo E, Möller I, de Miguel E, Batlle-Gualda E, Acebes C, Brito E, Mayordomo L, Moragues C, Uson J, de Agustín JJ, Martínez A, Rejón E, Rodríguez A, Daudén E. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology (Oxford) 2011; 50: 1838-1848 [PMID: 21706682 DOI: 10.1093/rheumatology/ker078]

Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64 Suppl 2: ii74-ii77 [PMID: 15708943]

Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum 2007; 37: 164-173 [PMID: 17570469 DOI: 10.1016/j.semarthrit.2007.03.004]

Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowycz E, Kyle S, McNnes JB, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh NJ. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) 2013; 52: 1754-1757 [PMID: 23887065 DOI: 10.1093/rheumatology/ket187]

Carneiro S, Azevedo VF, Bonfiglioli R, Ranza R, Gonçalves CR, Keiserman M, Meirelles Éde S, Pinheiro Mde M, Ximenes AC, Bernardo W, Sampaio-Barros PD. Recommendations for the management and treatment of psoriatic arthritis. Rev Bras Reumatol 2013; 53: 227-241 [PMID: 24051907]

Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71: 319-326 [PMID: 21803753 DOI: 10.1136/ard.2011.150995]

Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013; 7: 201-210 [PMID: 23569359 DOI: 10.2147/DDDT.S32713]

P- Reviewer: Chen GS, La Montagna G
S- Editor: Gou SX
L- Editor: A
E- Editor: Wu HL
